Loading provider…
Loading provider…
Hematology & Oncology Physician in New Orleans, LA
NPI: 1396712808Primary Practice Location
TOURO INFIRMARY
1401 Foucher St, New Orleans, LA
Primary Employer
Crescent City Physicians, Inc.
crescentcityphysicians.com
HQ Phone
Get MD Jayne's Phone Numberphone_androidMobile
Get MD Jayne's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardLA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 255 | 747 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 31 | 46 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 11 | 12 |
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.
Authors: Rakesh Jain, Weijing Sun, Francis Nugent, Keith Stuart, Mary Mulcahy
Publication Date: 2013-10-04
Authors: Jorge Garcia, Jorge Garcia, Toni Choueiri, Shailender Bhatia, Gary Hudes
Journal: Cancer
Publication Date: 2014-02-27
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
Authors: Mark Keaton, Karel Dicke
Publication Date: 2011-03-10
Lead Sponsor: EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Intervention / Treatment: DRUG: Capecitabine, OTHER: Best supportive care, DRUG: Avelumab, DRUG: Oxaliplatin, DRUG: Leucovorin, DRUG: 5-Fluorouracil
Lead Sponsor: Bavarian Nordic
Intervention / Treatment: BIOLOGICAL: Nivolumab, BIOLOGICAL: Pembrolizumab, BIOLOGICAL: CV301
Lead Sponsor: EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Intervention / Treatment: DRUG: Paclitaxel, DRUG: Avelumab, DRUG: Irinotecan, OTHER: Best Supportive Care (BSC)